Multiple-Dose Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with HIV-1 Infection

Simple item page
dc.contributor.authorCahn, Pedro
dc.contributor.authorRolón, María José
dc.contributor.authorCassetti, Isabel
dc.contributor.authorShiveley, LeeAnn
dc.contributor.authorHoldich, Tom
dc.contributor.authorSawyer, James
dc.date.accessioned2024-05-23T18:53:35Z
dc.date.available2024-05-23T18:53:35Z
dc.date.issued2008
dc.description.abstractBackground and objective: This study aimed to investigate the multiple-dose pharmacokinetics of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in antiretroviral-naive patients with HIV-1 infection. Methods: This was an international, randomized, double-blind, placebo-controlled, multicentre, dose-ranging study. Patients received 10 days' oral placebo or apricitabine 200, 400, 600 or 800 mg twice daily or 800 or 1200 mg once daily. On days 1 and 8, blood and urine samples were collected over 24 hours for pharmacokinetic analysis. Apricitabine triphosphate pharmacokinetics were investigated in peripheral blood mononuclear cells (PBMCs) on day 8. Results: Overall, 63 patients (mean age 33.9 +/- 8.7 years; mean weight 71.6 +/- 15.4 kg) were randomized, and 62 patients completed the study. Apricitabine was rapidly absorbed, with peak plasma concentrations attained within approximately 1.5-2.5 hours. Pharmacokinetics were linear over the range 200-800 mg twice daily. Apricitabine was predominantly excreted via the kidneys, with no significant accumulation during repeated administration. Steady-state conditions were attained by day 8. Apricitabine triphosphate exposure in PBMCs was roughly proportional to the dose of apricitabine across the dose range 200-800 mg twice daily, with adequate correlations between plasma exposure to apricitabine (9910 ng/mL per 65 kg for 800-mg twice-daily administration) and PBMC exposure to apricitabine triphosphate (maximum concentration [C(max)] = 5.55 +/- 1.94 pmol/million cells for 800-mg twice-daily administration). Apri-citabine was well tolerated. Conclusion: Apricitabine shows essentially linear pharmacokinetics during repeated administration in patients with HIV-1 infection.
dc.identifier.citationCahn, P., Rolon, M., Cassetti, I., Shiveley, L., Holdich, T., & Sawyer, J. (2008). Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection. Clinical Drug Investigation.
dc.identifier.otherDOI: 10.2165/00044011-200828020-00007
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/1129
dc.relation.ispartofseriesClinical Drug Investigation
dc.subjectApricitabine
dc.subjectPharmacokinetics
dc.subjectHIV-1 Infection
dc.subjectMultiple-Dose
dc.titleMultiple-Dose Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Patients with HIV-1 Infection

Files

Collections

Articulos científicos